Jim Sherblom has joined ReForm Biologics as chair to lead a new strategy. The ex-Genzyme executive arrives at ReForm as it switches focus to the development of subcutaneous versions of intravenous ...
A subcutaneous formulation of Johnson & Johnson’s BCMAxCD3 bispecific antibody teclistamab has achieved a 73% overall response rate in a small trial of heavily pretreated multiple myeloma patients.
Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback